About Revance Therapeutics (NASDAQ:RVNC)
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. Revance Therapeutics, Inc. has a collaboration agreement with Mylan N.V. (MYL) for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RVNC
CUSIPN/A
Phone510-742-3400
Debt
Debt-to-Equity RatioN/A
Current Ratio13.65%
Quick Ratio13.65%
Price-To-Earnings
Trailing P/E Ratio-7.07
Forward P/E Ratio-7.96
P/E GrowthN/A
Sales & Book Value
Annual Sales$260,000.00
Price / Sales4,004.98
Cash FlowN/A
Price / CashN/A
Book Value$7.51 per share
Price / Book3.77
Profitability
EPS (Most Recent Fiscal Year)($4.01)
Net Income$-120,580,000.00
Net Margins-46,025.57%
Return on Equity-64.40%
Return on Assets-56.00%
Miscellaneous
Employees134
Outstanding Shares36,730,000
Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions
What is Revance Therapeutics' stock symbol?
Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."
How were Revance Therapeutics' earnings last quarter?
Revance Therapeutics Inc. (NASDAQ:RVNC) issued its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by $0.15. The biopharmaceutical company earned $0.04 million during the quarter, compared to analyst estimates of $0.09 million. Revance Therapeutics had a negative return on equity of 64.40% and a negative net margin of 46,025.57%. The company's revenue was down 50.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.95) EPS. View Revance Therapeutics' Earnings History.
What price target have analysts set for RVNC?
12 equities research analysts have issued twelve-month target prices for Revance Therapeutics' shares. Their forecasts range from $34.00 to $60.00. On average, they expect Revance Therapeutics' share price to reach $46.1818 in the next year. View Analyst Ratings for Revance Therapeutics.
What are Wall Street analysts saying about Revance Therapeutics stock?
Here are some recent quotes from research analysts about Revance Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "Today, RVNC announced four new senior roles for its commercialization team: Dustin Sjuts as VP Strategy and Sales, Aesthetics & Therapeutics; Ben Putman as VP Digital; Marc Korenberg as Sr Director of Commercial Operations; and Erica Bazerkanian has been promoted to VP Marketing, Aesthetics & Therapeutics." (4/2/2018)
- 2. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (3/6/2018)
Who are some of Revance Therapeutics' key competitors?
Some companies that are related to Revance Therapeutics include Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array BioPharma (ARRY), Tesaro (TSRO), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Evotec A.G. (EVTCY) and Ascendis Pharma (ASND).
Who are Revance Therapeutics' key executives?
Revance Therapeutics' management team includes the folowing people:
- Mr. L. Daniel Browne, Co-Founder, CEO, Pres & Director (Age 56)
- Dr. Abhay Joshi, Chief Operating Officer (Age 55)
- Mr. Todd Erik Zavodnick, Chief Commercial Officer and Pres of Aesthetics & Therapeutics (Age 46)
- Ms. Lauren P. Silvernail, CFO, Chief Bus. Officer & Principal Accounting Officer (Age 59)
- Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications
Has Revance Therapeutics been receiving favorable news coverage?
Media coverage about RVNC stock has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Revance Therapeutics earned a news impact score of 0.09 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 44.63 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Revance Therapeutics?
Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Revance Therapeutics' stock price today?
One share of RVNC stock can currently be purchased for approximately $28.35.
How big of a company is Revance Therapeutics?
Revance Therapeutics has a market capitalization of $1.09 billion and generates $260,000.00 in revenue each year. The biopharmaceutical company earns $-120,580,000.00 in net income (profit) each year or ($4.01) on an earnings per share basis. Revance Therapeutics employs 134 workers across the globe.
How can I contact Revance Therapeutics?
Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]
MarketBeat Community Rating for Revance Therapeutics (RVNC)
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe RVNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Revance Therapeutics (NASDAQ:RVNC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Revance Therapeutics in the last 12 months. Their average twelve-month price target is $46.1818, suggesting that the stock has a possible upside of 62.90%. The high price target for RVNC is $60.00 and the low price target for RVNC is $34.00. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.92 | 2.92 | 2.89 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $46.1818 | $46.7273 | $46.1111 | $37.00 |
| Price Target Upside: | 62.90% upside | 52.70% upside | 37.24% upside | 45.67% upside |
Revance Therapeutics (NASDAQ:RVNC) Consensus Price Target History
Revance Therapeutics (NASDAQ:RVNC) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Revance Therapeutics (NASDAQ:RVNC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Revance Therapeutics (NASDAQ RVNC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.05%
Institutional Ownership Percentage: 95.06%
Revance Therapeutics (NASDAQ RVNC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/22/2018 | Lauren P Silvernail | CFO | Sell | 3,431 | $30.85 | $105,846.35 | 68,371 |  |
| 3/16/2018 | L Daniel Browne | CEO | Sell | 6,452 | $31.64 | $204,141.28 | 130,208 | |
| 3/16/2018 | Phyllis Gardner | Director | Sell | 5,333 | $31.51 | $168,042.83 | 5,250 | |
| 3/13/2018 | Lauren P Silvernail | CFO | Sell | 25,867 | $34.50 | $892,411.50 | 98,821 | |
| 3/9/2018 | Lauren P Silvernail | CFO | Sell | 20,000 | $32.00 | $640,000.00 | 82,954 | |
| 3/7/2018 | L Daniel Browne | CEO | Sell | 27,283 | $31.43 | $857,504.69 | 131,208 | |
| 3/7/2018 | Lauren P Silvernail | CFO | Sell | 10,000 | $31.50 | $315,000.00 | 82,954 | |
| 11/22/2017 | L Daniel Browne | CEO | Sell | 7,600 | $24.94 | $189,544.00 | 133,188 | |
| 11/7/2017 | Lauren P Silvernail | CFO | Sell | 10,000 | $26.83 | $268,300.00 | 59,006 | |
| 11/7/2017 | Mark J Foley | Director | Buy | 20,000 | $26.96 | $539,200.00 | 6,000 | |
| 10/18/2017 | L Daniel Browne | CEO | Sell | 7,662 | $26.16 | $200,437.92 | 140,788 | |
| 10/12/2017 | Lauren P Silvernail | CFO | Sell | 11,164 | $26.67 | $297,743.88 | | |
| 9/20/2017 | L Daniel Browne | CEO | Sell | 7,600 | $23.58 | $179,208.00 | 148,450 | |
| 8/23/2017 | L Daniel Browne | CEO | Sell | 22,800 | $22.76 | $518,928.00 | 178,850 | |
| 5/24/2017 | L Daniel Browne | CEO | Sell | 19,713 | $20.35 | $401,159.55 | 183,932 | |
| 5/22/2017 | L Daniel Browne | CEO | Sell | 12,287 | $20.20 | $248,197.40 | 183,932 | |
| 5/22/2017 | Lauren P Silvernail | CFO | Sell | 1,793 | $20.20 | $36,218.60 | 36,566 | |
| 1/25/2017 | L Daniel Browne | CEO | Sell | 12,000 | $19.78 | $237,360.00 | 184,627 | |
| 12/28/2016 | L Daniel Browne | CEO | Sell | 12,000 | $20.94 | $251,280.00 | 195,627 | |
| 11/25/2016 | L Daniel Browne | CEO | Sell | 12,000 | $17.92 | $215,040.00 | 208,449 | |
| 10/26/2016 | L Daniel Browne | CEO | Sell | 12,000 | $14.85 | $178,200.00 | 219,627 | |
| 6/13/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $18.25 | $18,250.00 | 24,944 | |
| 5/9/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $16.18 | $16,180.00 | 26,264 | |
| 4/11/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $19.11 | $19,110.00 | 26,264 | |
| 3/7/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $20.43 | $20,430.00 | 26,264 | |
| 2/8/2016 | Curtis Ruegg | EVP | Sell | 1,000 | $18.14 | $18,140.00 | 17,264 | |
| 1/6/2016 | Curtis Ruegg | EVP | Sell | 2,000 | $33.06 | $66,120.00 | 18,027 | |
| 11/17/2015 | Arthur Peter Bertolino | EVP | Sell | 7,753 | $39.11 | $303,219.83 | 34,001 | |
| 8/17/2015 | Curtis Ruegg | EVP | Sell | 3,000 | $30.33 | $90,990.00 | 18,027 | |
| 7/17/2015 | Curtis Ruegg | EVP | Sell | 3,000 | $31.03 | $93,090.00 | | |
| 6/17/2015 | Curtis Ruegg | EVP | Sell | 3,000 | $33.53 | $100,590.00 | | |
| 5/18/2015 | Curtis Ruegg | EVP | Sell | 3,000 | $26.42 | $79,260.00 | | |
| 4/17/2015 | Curtis Ruegg | EVP | Sell | 2,000 | $22.23 | $44,460.00 | | |
| 3/17/2015 | Curtis Ruegg | EVP | Sell | 1,500 | $18.61 | $27,915.00 | | |
| 3/9/2015 | Curtis Ruegg | EVP | Sell | 500 | $18.00 | $9,000.00 | | |
| 2/17/2015 | Curtis Ruegg | EVP | Sell | 1,000 | $16.80 | $16,800.00 | | |
| 1/20/2015 | Curtis Ruegg | EVP | Sell | 1,000 | $17.25 | $17,250.00 | | |
| 12/17/2014 | Curtis Ruegg | EVP | Sell | 1,000 | $16.45 | $16,450.00 | | |
| 11/28/2014 | L Daniel Browne | CEO | Buy | 6,000 | $16.67 | $100,020.00 | | |
| 11/18/2014 | Curtis Ruegg | EVP | Sell | 1,000 | $16.00 | $16,000.00 | | |
| 9/17/2014 | Curtis Ruegg | EVP | Sell | 2,000 | $20.55 | $41,100.00 | | |
| 9/17/2014 | Jacob Waugh | Insider | Sell | 97,713 | $20.73 | $2,025,590.49 | | |
(Data available from 1/1/2013 forward)
Revance Therapeutics (NASDAQ RVNC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018
finance.yahoo.com - April 25 at 4:55 PM |
| Revance Therapeutics to Release First Quarter 2018 Financial Results on Tuesday, May 8, 2018
finance.yahoo.com - April 24 at 5:01 PM |
 | Revance Therapeutics Inc. (RVNC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 21 at 1:36 AM |
| Revance Therapeutics' (RVNC) "Hold" Rating Reaffirmed at Guggenheim
www.americanbankingnews.com - April 20 at 4:17 PM |
| Revance Therapeutics (RVNC) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - April 20 at 11:54 AM |
| Mizuho Trims Revance Therapeutics (RVNC) Target Price to $48.00
www.americanbankingnews.com - April 20 at 7:46 AM |
 | Revance sees U.S. marketing application for Botox competitor RT002 in H1 2019
seekingalpha.com - April 19 at 4:58 PM |
 | Revance Investor Day Highlights New Neuroscience Indications in Development
www.bizjournals.com - April 19 at 4:58 PM |
| Revance Therapeutics: Cramer's Top Takeaways
finance.yahoo.com - April 19 at 9:00 AM |
| BidaskClub Downgrades Revance Therapeutics (RVNC) to Hold
www.americanbankingnews.com - April 18 at 5:18 PM |
| Revance Therapeutics (RVNC) Given a $28.00 Price Target by Piper Jaffray Analysts
www.americanbankingnews.com - April 15 at 11:42 PM |
| Revance Therapeutics Inc. (RVNC) Expected to Announce Quarterly Sales of $12.68 Million
www.americanbankingnews.com - April 13 at 2:37 AM |
| Revance Therapeutics (RVNC) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 12 at 12:01 PM |
| Revance Therapeutics Inc. (RVNC) Expected to Announce Earnings of -$0.63 Per Share
www.americanbankingnews.com - April 11 at 3:13 PM |
| Revance Therapeutics (RVNC) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 10 at 8:54 PM |
| Revance Therapeutics (RVNC) PT Set at $50.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 5 at 8:30 PM |
 | Revance Therapeutics Inc Is Set to Shake Up the Botox Market
investorplace.com - April 4 at 11:01 AM |
| Revance beefs up commercial team ahead of launch of Botox competitor RT002
seekingalpha.com - April 3 at 9:16 AM |
| Revance Therapeutics (RVNC) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 12:31 AM |
| Revance Therapeutics' (RVNC) Buy Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - April 2 at 9:10 PM |
| Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 Injectable
finance.yahoo.com - April 2 at 4:52 PM |
| Revance Therapeutics (RVNC) Cut to Hold at Guggenheim
www.americanbankingnews.com - March 30 at 12:56 AM |
| Revance Therapeutics (RVNC) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 28 at 4:46 PM |
| Revance Therapeutics Inc (RVNC) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 27 at 1:38 AM |
| Revance Therapeutics (RVNC) Now Covered by Analysts at Needham & Company LLC
www.americanbankingnews.com - March 26 at 5:24 PM |
| Revance to Host Investor Day on April 19, 2018
finance.yahoo.com - March 26 at 4:41 PM |
| -$0.63 EPS Expected for Revance Therapeutics Inc (RVNC) This Quarter
www.americanbankingnews.com - March 25 at 5:18 PM |
| Revance Therapeutics (RVNC) Downgraded to Strong Sell at BidaskClub
www.americanbankingnews.com - March 25 at 9:50 AM |
| Revance Therapeutics Inc (RVNC) CFO Lauren P. Silvernail Sells 3,431 Shares
www.americanbankingnews.com - March 23 at 10:14 PM |
 | Allergan's Battered Shares Are Poised To Rise Over 35 ... - Investopedia (blog)
www.investopedia.com - March 22 at 4:55 PM |
| Edited Transcript of RVNC earnings conference call or presentation 28-Feb-18 9:30pm GMT
finance.yahoo.com - March 21 at 10:00 AM |
| Revance to Participate in the Needham Healthcare Conference
finance.yahoo.com - March 20 at 4:41 PM |
| Revance Therapeutics Inc (RVNC) CEO Sells $204,141.28 in Stock
www.americanbankingnews.com - March 16 at 10:10 PM |
| Phyllis Gardner Sells 5,333 Shares of Revance Therapeutics Inc (RVNC) Stock
www.americanbankingnews.com - March 16 at 10:10 PM |
| Revance Therapeutics Inc (RVNC) CFO Lauren P. Silvernail Sells 25,867 Shares
www.americanbankingnews.com - March 15 at 10:08 PM |
 | Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts
feeds.benzinga.com - March 13 at 4:48 PM |
| Analysts Anticipate Revance Therapeutics Inc (RVNC) Will Post Quarterly Sales of $12.68 Million
www.americanbankingnews.com - March 10 at 10:02 AM |
| Lauren P. Silvernail Sells 10,000 Shares of Revance Therapeutics Inc (RVNC) Stock
www.americanbankingnews.com - March 9 at 9:28 PM |
| Revance Therapeutics Inc (RVNC) CEO L Daniel Browne Sells 27,283 Shares
www.americanbankingnews.com - March 9 at 9:15 PM |
| Insider Selling: Revance Therapeutics Inc (RVNC) CFO Sells 20,000 Shares of Stock
www.americanbankingnews.com - March 9 at 9:15 PM |
| Revance Therapeutics Inc (RVNC) Expected to Post Earnings of -$0.69 Per Share
www.americanbankingnews.com - March 8 at 4:29 PM |
| FY2018 EPS Estimates for Revance Therapeutics Inc (RVNC) Reduced by Analyst
www.americanbankingnews.com - March 7 at 11:50 AM |
| Revance Therapeutics (RVNC) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 6 at 8:04 PM |
| Revance to Participate in Upcoming Investor Conferences
finance.yahoo.com - March 6 at 5:06 PM |
| Goldman Sachs Sees 100% Upside In This Biopharma Company
finance.yahoo.com - March 6 at 8:56 AM |
| Revance Therapeutics (RVNC) Research Coverage Started at Goldman Sachs Group
www.americanbankingnews.com - March 5 at 7:54 PM |
| Senzar Asset Management LLC Invests $8.45 Million in Revance Therapeutics Inc (RVNC) Stock
www.americanbankingnews.com - March 5 at 3:44 PM |
| FY2022 EPS Estimates for Revance Therapeutics Inc (RVNC) Decreased by SunTrust Banks
www.americanbankingnews.com - March 5 at 9:44 AM |
| Revance Therapeutics Inc to Post Q1 2018 Earnings of ($0.20) Per Share, William Blair Forecasts (RVNC)
www.americanbankingnews.com - March 5 at 1:46 AM |
| Revance Therapeutics Inc (RVNC) Shares Bought by Bank of New York Mellon Corp
www.americanbankingnews.com - March 4 at 4:44 AM |
Revance Therapeutics (NASDAQ:RVNC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Revance Therapeutics (NASDAQ:RVNC) Income Statement, Balance Sheet and Cash Flow Statement
Revance Therapeutics (NASDAQ RVNC) Stock Chart for Thursday, April, 26, 2018
Loading chart…
